Buradasınız

Anasayfa » Content

Hodgkin dışı lenfomada lenf bezi ince iğne aspirasyonu örneklerindeki P glikoprotein ekspresyonu

P glycoprotein expression in fine needle aspiration specimens from lymp nodes of non-hodgkin's lymphoma

Journal Name:

  • Selçuk Tıp Dergisi

Publication Year:

  • 2002

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
We studied P glycoprotein (Pgp) expression by testing fine needle aspiration specimens from lymp nodes with C-494 antibody using an immunocytochemical assay in 30 cases of histologicaily proven non-Hodgkin's lymphoma (NHL) at diagnosis and after three courses of chemotherapy. Pgp expression was detected in two of eight patients with stage l-ll, 10 of 22 patients with stage lll-IV at diagnosis and in one of two patients with stage /-//, three of eight patients with stage lll-IV after chemotherpy. The stage of disease, the presence of B symptoms, the rate of response to treatment and duration of overall survival showed no significant difference between the group of Pgp negafive patients ad the group of Pgp positive patients. İn conclucion we suggest that Pgp expression alone can not explain the treatment of chemotherapy resistance in NHL probabiy due to multifuctorial mechanisms of drug resistance.
Bookmark/Search this post with
Abstract (Original Language): 
Histolojik olarak Hodgkin dışı lenfoma (HDL) olduğu ispatlanmış 30 olgunun lenf bezlerinin ince iğne aspirasyonu örneklerinde, C-494 antikoru kullanarak immunositokimyasat bir test yöntemiyle, P glikoprotein (Pgp) ekspres-yonunu tanıdı ve üç kür kemoterapi sonrasında inceledik. Pgp ekspresyonu tamda; evde l-U'deki iki hastanın birinde, evre lll-IV'deki sekiz hastanın üçünde saptandı. Hastalık evresi, B semptomlarının varlığı, tedaviye cevap oranı ve toplam sağkalım süresi, Pgp negatif ve Pgp pozitif hasta grupları arasında anlamlı bir fark göstermedi. Sonuç olarak Pgp ekspresyonunun, olası ilaç direncinin diğer çok etmenli mekanizmalar nedini ile, HDL'da kemoterapiye olan direnci tek başına açıklayamayacağnı ileri sürmekteyiz.
FULL TEXT (PDF): 
PDF icon arastirmax-hodgkin-disi-lenfomada-lenf-bezi-ince-igne-aspirasyonu-orneklerindeki-p-glikoprotein-ekspresyonu.pdf
  • 3
177-183
  • Turkish

REFERENCES

References: 

1. Rodriguez C, Commes T, Robert J, Rossi J-F. Expression of P-glycoprotein and anionic glutathion s-transferase genes in non-Hodgkin's lymphoma. Leukemia Res 1993:17:149-56.
2. Burger H, Nooter K, Sonnevelt P, van VVingerden KE, Zaman GJR. Stater G. High expression of the multîdrug reslsitance-associated protein (MRP) in chronic and prolymphocytic leukaemia. Br J Haemat 1994;88:348-56.
3. Marie JP, Zhou DC, Gurbuxani S, Legrand O, Ziîtoun R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996;32A:1034-8.
4. Kaye Stanley B. Clinîcal drug resistance: The role of factors other than p:glycoprotein. Am J Med 1995;99(supp! 6a):40-4.
5. Covelli A. Modulation of multidrug resistance (MDR) in hematological malignancies. Ann Oncol 1999;10:53-9.
6. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BGM, Taylor CW et al. Drug resistance in multipl myeloma and non-Hodgkin's lymphoma. Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-24.
7. Fisher Rl, Gaynor ER, Dahlberg S. Phase III compari-son of CHOP vs. n-BACOD vs. ProMACE-CytaBOM vs. MACOP-B in patient with intermediate or high-grade non-Hodgkin lymphoma study. N Engl J Med 1993;328:1002.
8. Dalton WS. Alternative (non-p-glycoprotein) mecha-nisms of drug resistance in non-Hodgkin's lymphoma. Hematoi Oncol Clin N Am 1997;11: 975-86.
9. Burt RK, Fojo AT, Thorgeirsson SS. Multidrug resist-ance due to p-glycoprotein. Hospital Practice 1990: 15:67-78.
10. Morrow CS, Cowan KH. Mechanisms and clinical sig-nificance of multidrug resistance. Oncology 1988;2:55-
67.

11. Chan H SL, DeBoer G, Thorner PS, Haddad G, Ling V. Multidrug resistance. Clinical opportunities in diagnosis and cîrcmvention. Hematoi Oncol Clin N Am 1994:8:383-410.
12. Nielsen D, Skovsgaard T: P-glycoprotein as multidrug transporter: a critical review of current multidrug resist-ance celi lines. Biochim Biophys Açta 1992;1139:169-83.
13. Jeffrey A. Moscow, Cowan KH: Multidrug resistance. Cancer Chemoterapy and Biological Responce 1990;97-114
14. VVeinstein RS, Jakate SM, Dominguez JM, Lebovitz MD, Koukoulis GK, Kuszak JR et al. Relationship of the expression of the multidrug resistance gene product (p-glycoprotein) in human colon carsinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res 1991;51:2720-6.
15. lzqueierdo MA, Shoemaker RH, Flens MJ. Scheffer GL, VVu L, Prather TR et al. Overlapping phnotypes of mul¬tidrug resistance among panels of human cancer celi lines. Int. J. Cancer 1996;65:230-7.
16. VVilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy, J Clin Oncol 1995; 13:1995-2004.
17. Goldstein LJ, Pastan I, Gottesman MM. Multidrug resistance in human cancer. Crİt Rev Oncol Hematoi 1992;12(3):243-53.
18. Chabner BA, VVilson VVyndham. Revelsal of multidrug resistance. J Clin Oncol 1991;19:4-6.
19. VVeinstein RD, Kuzsak JR, Kluskens LF, Coon JS: P-glycoprotein in pathology: The multidrug resistance gene family in humans. Hum Pathol 1990;21:34-48.
20. Attal M, Bibeau F, Müller C, Duchayne E, Kuhlein E, Cassar G et al. Optimization of immunohistochemical detection of P-glycoprotein in chronic lymhoîd disor-ders. Am J Clin Pathol 1994;102:842-9.

21. Drenou B. Lamy T, Amiot L. Fardei O. Caulet-Maugendre S, Sasportes M et al. CD3" CD56* non-Hodgkin's lymphomas wiht an aggressive behavior related to multidrug resistance. Blood 1997:89:2966¬74.
22. Delville JP, Pradier O. Pauwels O, Van Onderbergen A. Kiss R, Feremans W et al. Comparatİve study of mul¬tidrug resistance evaluated by means of the quantita-tive immunohistochemîcal detection of p-glycoprotein and functional release of rhodamine 123. Am J Hematoi 1995;49:183-93.
23. Chabner B, Bates S, Fojo A, Spolyar M. VVilson W. Drug resistance in adult lymphomas. Semin Hematoi 1994;31:70-87.
24. Yuen AR. Sicik BL. Multidrug resistance in lymphomas. J Clin Onc 1994;12:2453-9.
25. Lee JJ, Hughes CS, Fine RL. Page RL. P-giycoproteİn expression İn canine lymphoma. Cancer 1996:77:1892¬8.
26. Jaffe ES, Harris NL, Diebold J. VVork Health Organization Classification of Lymphomas: a work in progress. Ann Oncoî 1998;9(suppl 5):25-30.
27. Egashİra M, Kawamata N, Sugitomo K, Kaneko T, Oshimi K. P-glycoprotein expression on normal and abnormally expanded natural killer cells and inhibition of p-glycoprotien function by cyclosporin A and its ana-logue, PSC833. Blood 19999; 93:599-606.

28. Seymour L, Bezwoda WR, Dansey RD. P-glycoprotein immunostaining correlates wiht Er and wîth hig Kİ67 expression but faüs to predict anthracycline resistance in patients with advanced breast cancer. Breast Cancer Research and Treatment 1995;36:61-9.
29. Pileri SA, Sabattini E, Falini B, Tazzarı PL, Gheriinzoni F, Michieli MG, et al. İmmunohistochemîcal detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. Histopathology. 1991;19(2):131-40.
30. Dan S. Esumi M, Sawada U. Hayashi N. Uchida T, Yamazaki T, et al. Expression of a multidrug-resistance gene in human malignant lymphoma and related disor-ders. Leuk Res. 1991;15{12):1139-43.
31. Miller TP, Grogan TM, Dalton WS. P-giycoprotein expression in malignant lymphoma and reversal of clin¬ical drug resistance witn chemotherapy plus high-dose verapamil. J Clin Oncol 1991;9:17-24.
32. Yuen AR, Breslin S. Sikic BL Horning SJ. A phase l/ll trial of ONCEP chemotherapy with the multidrug resist¬ance modulator PSC 833 in patients with recurrent or refractory non-Hodgkin's lymphoma. American Society of Clinical Oncology, 34th Annual Meeting, 1998; Abstract48.

Thank you for copying data from http://www.arastirmax.com